Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)
doi 10.1136/annrheumdis-2019-eular.960
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism